- Sun Life Financial’s 1Q underlying EPS was C$1.50, falling short of the estimated C$1.65.
- The company’s assets under management were at C$1.47 trillion, surpassing the estimated C$618.01 billion.
- The underlying Return on Equity (ROE) was 16%, slightly below the estimated 17.9%.
- Sun Life held cash and other equivalents amounting to C$495 million.
- The company’s underlying earnings were impacted by three main factors: the sale of Sun Life UK, higher morbidity claims, and the ending of the Public Health Emergency in the U.S.
- Ratings on the company’s stock were mixed with 9 buys, 5 holds and 1 sell.
A look at Sun Life Financial Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
When looking at the long-term outlook for Sun Life Financial, the Smartkarma Smart Scores paint a positive picture. With solid scores across key factors, the company appears well-positioned for the future. Sun Life Financial scores well in areas such as Dividend, Resilience, and Momentum, indicating strength in these crucial aspects. This suggests that the company is performing well in terms of its financial health, ability to withstand market fluctuations, and momentum in its operations.
As an international financial services organization offering a wide range of products and services, Sun Life Financial has established itself as a trusted provider of wealth accumulation and protection solutions. Serving both individual and corporate clients globally, the company’s strong performance across various Smart Scores reflects its overall stability and potential for growth in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
